Advertisement
Canada markets close in 5 hours 1 minute
  • S&P/TSX

    22,007.47
    +135.51 (+0.62%)
     
  • S&P 500

    5,067.88
    +57.28 (+1.14%)
     
  • DOW

    38,497.68
    +257.70 (+0.67%)
     
  • CAD/USD

    0.7317
    +0.0016 (+0.22%)
     
  • CRUDE OIL

    82.32
    +0.42 (+0.51%)
     
  • Bitcoin CAD

    91,545.34
    +1,265.77 (+1.40%)
     
  • CMC Crypto 200

    1,438.44
    +23.68 (+1.67%)
     
  • GOLD FUTURES

    2,331.30
    -15.10 (-0.64%)
     
  • RUSSELL 2000

    2,002.18
    +34.70 (+1.76%)
     
  • 10-Yr Bond

    4.5880
    -0.0350 (-0.76%)
     
  • NASDAQ

    15,682.58
    +231.28 (+1.50%)
     
  • VOLATILITY

    16.28
    -0.66 (-3.90%)
     
  • FTSE

    8,038.69
    +14.82 (+0.18%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • CAD/EUR

    0.6835
    -0.0015 (-0.22%)
     

Teva Pharmaceutical’s Generic Medicines Segment in 2017

Teva Pharmaceutical’s Generic Medicines Segment in 2017

In fiscal 2017, Teva Pharmaceutical Industries’ (TEVA) generic medicines segment reported revenues of $12.3 billion compared to $12 billion in 2016, which was a 2% YoY (year-over-year) growth.